Charles Schwab
SLRN

Charles Schwab’s ACELYRIN SLRN Stock Holding History

Charles Schwab’s Portfolio SLRN Stock Details SLRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-544,575
Closed -$1.35M – 3566
2025
Q1 		$1.35M Sell
544,575
-69,899
-11% -$166K ﹤0.01% 2736
2024
Q4 		$1.93M Buy
614,474
+4,796
+0.8% +$23.2K ﹤0.01% 2691
2024
Q3 		$3.01M Buy
609,678
+273,604
+81% +$1.41M ﹤0.01% 2586
2024
Q2 		$1.48M Sell
336,074
-4,797
-1% -$22.5K ﹤0.01% 2793
2024
Q1 		$2.3M Buy
340,871
+93,115
+38% +$707K ﹤0.01% 2549
2023
Q4 		$1.85M Buy
247,756
+3,934
+2% +$33.6K ﹤0.01% 2644
2023
Q3 		$2.48M Buy
243,822
+84,574
+53% +$1.8M ﹤0.01% 2537
2023
Q2 		$3.33M Buy
+159,248
New +$3.26M ﹤0.01% 2387

Other funds holding SLRN

Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Charles Schwab's SLRN Position: Q2 2025 in Review

Charles Schwab sold out of ACELYRIN (SLRN) in Q2 2025, closing a stake of 544,575 shares — an estimated $1.35M sold.

Charles Schwab first reported a position in SLRN in Q2 2023 and held it in 8 quarters. The position peaked at $3.33M in Q2 2023. 2 funds tracked by Wall St. Rank hold SLRN as of Q2 2025.

  • Charles Schwab reported no remaining ACELYRIN position as of Q2 2025 after selling out during the quarter.
  • Charles Schwab sold 544,575 ACELYRIN shares in Q2 2025, an estimated $1.35M.
  • Charles Schwab first reported a position in ACELYRIN in Q2 2023 and held it in 8 quarters.
  • Charles Schwab's ACELYRIN position peaked at $3.33M in Q2 2023.
  • 2 funds tracked by Wall St. Rank held ACELYRIN as of Q2 2025.

Based on Charles Schwab's 13F filing for Q2 2025, filed 12 Aug 2025.